SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001618835-22-000019
Filing Date
2022-02-16
Accepted
2022-02-16 06:22:30
Documents
17
Period of Report
2022-02-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evfm-20220215.htm   iXBRL 8-K 51208
2 EX-5.1 exhibit51opinion_february2.htm EX-5.1 11253
3 EX-10.1 evfm-ex101xcommonstockpurc.htm EX-10.1 666872
8 mintzfootera.jpg GRAPHIC 20083
9 mintzlogoa.jpg GRAPHIC 12460
  Complete submission text file 0001618835-22-000019.txt   1056095

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20220215.xsd EX-101.SCH 2292
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT evfm-20220215_def.xml EX-101.DEF 16429
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20220215_lab.xml EX-101.LAB 31730
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20220215_pre.xml EX-101.PRE 17165
11 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20220215_htm.xml XML 14007
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 22641457
SIC: 2834 Pharmaceutical Preparations